PROCEPT BioRobotics Corporation

Fundamentals6.0
Price Action6.0
News Sentiment5.0
AI Rating
5.0

Key Drivers

  • Strong gross margin
  • Large operating loss
  • Healthy liquidity

AI
AI Summary

5.0

PRCT's investment case has shifted from growth-for-growth's-sake to a binary, execution-and-governance bet—product-level unit economics and a healthy cash buffer matter, but near-term returns now hinge on consistent procedure utilization/consumable pull-through, credible forward guidance, and resolution/containment of securities investigations. Actionable stance: require consecutive revenue/adjusted‑EBITDA beats with visible handpiece-per-system growth or else avoid exposure given legal and cash‑burn tail risks.

GrowthOpportunity
Legal
CashRunway‍

Price Chart

Loading chart...

Financial Metrics

-
Revenue (TTM)
-
Net Income (TTM)
-
EPS (Q)
-
MCAP

Deep Analysis

Research tool. Not personalized advice.

Fundamental Analysis

6.0

Key Financial Insights:

  • Strong gross margin
  • Large operating loss
  • Healthy liquidity

PRCT is cash-rich with strong gross margins and very low short-term liquidity risk but is unprofitable at the operating level—sustaining large operating losses, negative cash flow and depressed returns despite modest leverage.

CashRich
Unprofitable

Price Behavior

6.0
Research tool. Not personalized advice. Technical analysis is for informational purposes only.

Key Price Behavior Insights:

  • Slight downtrend
  • 27.8–28 resistance
  • 22.7 key support

PRCT is in a modest downtrend over the last month, trading just below its ~ $26 last-month average, with clear resistance at $27.8–$28.0 and support near $22.69 (intraperiod support around $24s), so a decisive move above $28 on strong volume would signal a reversal while a break below $22.69 warns of deeper downside.

bearish
watchlist
Support Level: $22.69 (secondary: ~$24.17)
Resistance Level: $27.8–$28.0

Rapid drop on 2026-02-26–02-27 followed by sharp recovery into 2026-03-16 peak

Sentiment & News

5.0

Key News Insights:

  • Guidance miss
  • Legal probes
  • Insider/institutional buying

Procept BioRobotics missed Q4 and FY targets and reported a larger-than-expected adjusted EBITDA loss, prompting multiple investor lawsuits and heightened scrutiny in March 2026 despite some institutional and insider buying.

guidance_miss
litigation

Expect increased share volatility and downside pressure as litigation and disclosure risk undermine investor confidence